A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Jazz Pharmaceuticals
Arcus Biosciences, Inc.
Seagen Inc.
Qurient Co., Ltd.
USWM, LLC (dba US WorldMeds)
Amgen
Novartis
Taiho Oncology, Inc.
Legend Biotech USA Inc
NeoTX Therapeutics Ltd.
BeOne Medicines
Astellas Pharma Inc
Immunitas Therapeutics
Sichuan Baili Pharmaceutical Co., Ltd.
Tempus AI
Bristol-Myers Squibb
Cybrexa Therapeutics
NextCure, Inc.
Revolution Medicines, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Adaptimmune